益肝康治疗慢性乙型肝炎肝纤维化365例疗效观察

Efficacy of Yigankang therapy in 365 chronic hepatitis B patients with liver fibrosis

目的探讨中药益肝康对慢性乙型肝炎、肝纤维化的疗效。方法将365例慢性乙型肝炎患者随机分为两组,治疗组(305例)给予益肝康袋装浓缩煎剂1袋,每日2次,对照组(60例)给予葡醛内酯(肝太乐)0.2 g,每日3次,水飞蓟宾140 mg,每日3次,治疗6个月。分别于治疗前后记述症状,观察肝、脾变化,检测肝功能、血清肝纤维化指标,肝组织病理,进行疗效评价。结果治疗组和对照组血浆透明质酸、层黏连蛋白和Ⅲ型前胶原水平间差别有统计学意义,(185.13±10.84)μg/L vs(121.43±10.91)μg/L,(175.03±7.14)μg/L vs(142.86±14.66)μg/L,(153.37±20.96)μg/L vs(128.00±18.52)μg/L(P<0.01);同时,治疗组患者症状改善,肝、脾回缩,肝功能明显好转,白蛋白水平升高。结论益肝康是治疗慢性肝病、肝纤维化的有效药物。

Objective To evaluate the effects of tradional Chinese drug Yigankang on chronic hepatitis B and liver fibrosis. Methods 365 patients were randomly divided into two groups. Treatment group（ n=305） was given Yigankang decoction （condense apozem, one bag a time, twice a day）, and control group （n=60） was given glucurolactone （0.2g, three times a day） and/or silymarine （140 mg,three times a day） for six months. Before and after treatment, the changes of symptom,liver and spleen as well as liver function,index of liver fibrosis and the biopsy of liver puncture were observed, and the curative effect was evaluated. Results There were significant difference in the plasma level of hyaluronic acid,laminin and procollagen Ⅲ between two groups, （185.13±10.84）μg/L vs （121.43±10.91）μg/L,（175.03±7.14）μg/L vs （142.86±14.66） μg/L,（153.37±20. 96）μg/L vs （128. 00±8.52）μg/L（ P〈0.01） ,meanwhile, in treatment group, the symptom of the patients improved, the liver and spleen shrank, the liver function became better and the level of plasma albumin increased. Conclusion Yigankang is safer and more effective for treating chronic hepatitis B and liver fibrosis.